View Older Stories View More Recent Stories
-
Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024
-
Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
-
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseas
-
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
-
Form SC 13G SERA PROGNOSTICS, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Surrozen (SRZN) Announces $192.5M Private Placement
-
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
-
Selux Diagnostics Announces Additional $48 Million in Funding
-
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
-
Leading healthcare fund manager RA Capital launches biotech ETFs
-
Form SC 13D/A Nkarta, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Avalo Reports 2023 Financial Results and Provides Business Updates
-
Form SC 13G Alto Neuroscience, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D LENZ Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
CervoMed (CRVO) Announces Up to $149.4M Private Placement Financing
-
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
-
Avalo Therapuetics (AVTX) Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
-
Form SC 13G Regulus Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CYBIN INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Nkarta (NKTX) Prices $240M Share and Warrant Offering at $10/sh
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
LENZ Therapeutics (LENZ) Completes Merger with Graphite Bio, Provides Update
-
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
-
Capstan Therapeutics Announces $175M Oversubscribed Series B Financing
-
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
-
Cybin Inc (CYBN) Closes $150M Share Placement
-
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
-
Geron Corp (GERN) Prices $150M Share and Warrant Offering at $3/sh
-
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
-
Cybin Inc (CYBN) Announces $150M Oversubscribed Private Placement at $0.43/sh
-
Announces Oversubscribed Private Placement of U.S. $150 Million
-
Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Form SC 13D/A PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth
-
Lexeo Therapeutics (LXEO) Announces Oversubscribed $95.0 Million Equity Financing
-
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
-
Graphite Corp. (GRPH) Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
-
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Aerovate Therapeutics (AVTE) Appoints Habib Dable as Board Chair
